Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 36353 results found since Jan 2013.
Multimodality Therapy for Patients With High-Risk Prostate Cancer: Current Status and Future Directions
Prostate cancer is the most commonly diagnosed cancer and second most common cause of cancer death in American men. Although high-risk disease accounts for less than 15% of diagnoses, high-risk prostate cancer patients have a cancer-specific mortality rate of 15% at 10 years. There is currently no consensus on the optimal management of high-risk disease because (1) there are different primary modalities available (ie, surgery, radiation), for which there are no randomized trials comparing efficacy; and (2) unstandardized timing of different therapies (ie, neoadjuvant v concurrent v adjuvant), which makes comparisons of eff...
Source: Seminars in Oncology - June 1, 2013 Category: Cancer & Oncology Authors: Nicholas G. Zaorsky, Edouard J. Trabulsi, Jianqing Lin, Robert B. Den Tags: Adam P. Dicker, MD, PhD, Leonard G. Gomella, MD, FACS, and Wm. Kevin Kelly, DO, Guest Editors Source Type: research
Re: Long-Term Results of Two Prospective Bladder-Sparing Trimodality Approaches for Invasive Bladder Cancer: Neoadjuvant Chemotherapy and Concurrent Radio-Chemotherapy
A. Zapatero, C. Martin De Vidales, R. Arellano, Y. Ibañez, G. Bocardo, M. Perez, M. Rabadan, F. García Vicente, J. A. Cruz Conde and C. Olivier Department of Radiation Oncology, Hospital Universitario de la Princesa, Instituto Investigación Sanitaria IP, Madrid, Spain
Source: The Journal of Urology - April 25, 2013 Category: Urology & Nephrology Authors: David P. Wood Tags: Urological Oncology: Bladder, Penis and Urethra Cancer, and Basic Principles of Oncology Source Type: research
Molecular biomarkers as predictors of response to neoadjuvant chemoradiation therapy in rectal cancer
Abstract: The standard management of locally advanced rectal cancer includes neoadjuvant chemoradiation therapy (CRT) with 5-fluorouracil (5-FU) and concurrent pelvic irradiation (RT) to 45–50.4Gy. This regimen results in downstaging in approximately 60% of patients and a pathological complete response (pCR) in 20%. Response to CRT is associated with improved rates of survival, local control, and sphincter preservation. However, some tumors are completely resistant to CRT; thus, non-responding patients experience only the toxicity of this treatment without any of its benefits. The ability to predict an individual patient...
Source: Seminars in Colon and Rectal Surgery - August 30, 2013 Category: Gastroenterology Authors: Sarah A. Milgrom, Julio Garcia-Aguilar Tags: Current Treatment of Rectal Cancer: Optimizing Surgery and Individualizing Chemoradiation Source Type: research
Ultra-low anterior resection following neoadjuvant chemoradiation for rectal cancer: The end of the 1-cm rule?
Abstract: The surgical management of rectal cancer has evolved as techniques have improved and the use of preoperative multimodality therapy has gained acceptance as the standard of care. One of the most dynamic areas regarding surgical resection of rectal cancer has been the issue of an oncologically safe distal resection margin. Despite recommendations for the minimum acceptable distal margin shrinking from 5cm to 2cm and now to 1cm over the past several decades, this question remains a topic of intense debate. Such discussion centering on the impact distal margins of resection can critically affect the ability to preser...
Source: Seminars in Colon and Rectal Surgery - August 30, 2013 Category: Gastroenterology Authors: Brian K. Bednarski, George J. Chang Tags: Current Treatment of Rectal Cancer: Optimizing Surgery and Individualizing Chemoradiation Source Type: research
Molecular biomarkers as predictors of response to neoadjuvant chemoradiation therapy in rectal cancer
Abstract: The standard management of locally advanced rectal cancer includes neoadjuvant chemoradiation therapy (CRT) with 5-fluorouracil (5-FU) and concurrent pelvic irradiation (RT) to 45–50.4Gy. This regimen results in downstaging in approximately 60% of patients and a pathological complete response (pCR) in 20%. Response to CRT is associated with improved rates of survival, local control, and sphincter preservation. However, some tumors are completely resistant to CRT; thus, non-responding patients experience only the toxicity of this treatment without any of its benefits. The ability to predict an individual patient...
Source: Seminars in Colon and Rectal Surgery - September 1, 2013 Category: Gastroenterology Authors: Sarah A. Milgrom, Julio Garcia-Aguilar Tags: Current Treatment of Rectal Cancer: Optimizing Surgery and Individualizing Chemoradiation Source Type: research
Ultra-low anterior resection following neoadjuvant chemoradiation for rectal cancer: The end of the 1-cm rule?
Abstract: The surgical management of rectal cancer has evolved as techniques have improved and the use of preoperative multimodality therapy has gained acceptance as the standard of care. One of the most dynamic areas regarding surgical resection of rectal cancer has been the issue of an oncologically safe distal resection margin. Despite recommendations for the minimum acceptable distal margin shrinking from 5cm to 2cm and now to 1cm over the past several decades, this question remains a topic of intense debate. Such discussion centering on the impact distal margins of resection can critically affect the ability to preser...
Source: Seminars in Colon and Rectal Surgery - September 1, 2013 Category: Gastroenterology Authors: Brian K. Bednarski, George J. Chang Tags: Current Treatment of Rectal Cancer: Optimizing Surgery and Individualizing Chemoradiation Source Type: research
Quantification of a Proteotypic Peptide from Protein C Inhibitor by Liquid Chromatography-Free SISCAPA-MALDI Mass Spectrometry: Application to Identification of Recurrence of Prostate Cancer Proteomics and Protein Markers
CONCLUSIONS:
The high-throughput, liquid chromatography–free SISCAPA-MALDI assay is capable of rapid quantification of proteotypic PCI and sTfR peptide analytes in complex serum samples. Decreased serum concentrations of the PCI peptide were found to be related to recurrence of prostate cancer in patients treated with radiation with or without hormone therapy. However, a larger cohort of patients will be required for unequivocal validation of the PCI peptide as a biomarker for clinical use.
Source: Clinical Chemistry - September 27, 2013 Category: Chemistry Authors: Razavi, M., Johnson, L. D. S., Lum, J. J., Kruppa, G., Anderson, N. L., Pearson, T. W. Tags: Proteomics and Protein Markers Source Type: research
Re: A Phase 2 Clinical Trial of Sequential Neoadjuvant Chemotherapy with Ifosfamide, Doxorubicin, and Gemcitabine Followed by Cisplatin, Gemcitabine, and Ifosfamide in Locally Advanced Urothelial Cancer: Final Results
A. O. Siefker-Radtke, C. P. Dinney, Y. Shen, D. L. Williams, A. M. Kamat, H. B. Grossman and R. E. Millikan Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
Source: The Journal of Urology - September 3, 2013 Category: Urology & Nephrology Authors: David P. Wood Tags: Urological Oncology: Bladder, Penis and Urethra Cancer, and Basic Principles of Oncology Source Type: research
Neoadjuvant and adjuvant chemotherapy combined with anatomical resection of feline injection‐site sarcoma: results in 21 cats
This study assesses the outcome of two combined treatment strategies for the treatment of feline injection‐site sarcoma (FISS). Twenty‐one cats with primary or recurrent FISS received 3 cycles of neoadjuvant chemotherapy with epirubicin (25 mg m−2), then an anatomical resection of the entire muscle compartment containing the tumour was performed based on the findings of co‐axial imaging. Cats then received a further 3 cycles of adjuvant chemotherapy. Follow‐up was performed by telephone contact with a median follow‐up time of 1072 days. Three cats (14%) developed local tumour recurrence at days 264, 6...
Source: Veterinary and Comparative Oncology - February 7, 2014 Category: Veterinary Research Authors: J. Bray, G. Polton Tags: Original Article Source Type: research
Preoperative endorectal brachytherapy in the treatment of locally advanced rectal cancer: Rethinking neoadjuvant treatment
Abstract: Prior to the introduction of preoperative treatment and modern surgical technique, recurrence rates for locally advanced rectal cancer ranged from 30% to 50%. Since the widespread adoption of total mesorectal excision and preoperative chemoradiation therapy (CRT), local recurrence rates have reduced considerably to only 5–10%. However, preoperative treatment comes at a cost with significant acute and late toxicity. Additionally, 2 standards of care have emerged—1 week of radiation alone vs 5 weeks of concurrent chemoradiation. In this review, we evaluate toxicity associated with preoperative treatment as well...
Source: Seminars in Colon and Rectal Surgery - February 22, 2014 Category: Gastroenterology Authors: Matthew C. Biagioli, Joseph M. Herman Tags: Innovative Radiotherapy Options for the Patient with Colon and Rectal Cancer Source Type: research
Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: Tolerance and efficacy
Abstract: Background: Rectal cancer predominantly affects the elderly. Unfortunately, this age category is under-represented in clinical trials because clinicians are loath to include patients with a high risk of comorbidity.Patients and methods: An exploratory analysis of the ACCORD12/PRODIGE 2 phase III trial was carried out to retrospectively compare the benefit of neoadjuvant chemotherapy between the elderly (⩾70years; n=142) and younger patients (
Source: Radiotherapy and Oncology - January 13, 2014 Category: Radiology Authors: Eric François, David Azria, Sophie Gourgou-Bourgade, Marta Jarlier, Isabelle Martel-Laffay, Christophe Hennequin, Pierre-Luc Etienne, Véronique Vendrely, Jean-François Seitz, Thierry Conroy, Beata Juzyna, Jean-Pierre Gerard Tags: Original Articles Source Type: research
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer
Conclusions: This phase I experience evaluating the tolerability of neoadjuvant SC-CRT with photon RT closed early due to unexpected intraoperative complications.
Source: Radiotherapy and Oncology - November 13, 2013 Category: Radiology Authors: Jennifer Y. Wo, Harvey J. Mamon, Cristina R. Ferrone, David P. Ryan, Lawrence S. Blaszkowsky, Eunice L. Kwak, Yolanda D. Tseng, Brian N. Napolitano, Marek Ancukiewicz, Richard S. Swanson, Keith D. Lillemoe, Carlos Fernandez-del Castillo, Theodore S. Hong Tags: Original Articles Source Type: research
Mastopexy sutures masquerading as an organic breast lesion on MRI scan
A 46-year-old lady with a previous history of benign breast disease presented to the Cambridge Breast Unit (CBU) with a palpable lump in the upper outer quadrant of her left breast. Mammograms were normal and ultrasound findings were benign but in accordance with the CBU protocol for discrete breast lesions, a clinically directed core biopsy was performed which revealed a grade II invasive ductal carcinoma. Breast MRI showed widespread multifocal disease with a main tumour mass of 46 mm × 44 mm × 27 mm. She was treated with neoadjuvant chemotherapy followed by a left skin-sparing mastectomy and level II axillary c...
Source: Journal of Plastic, Reconstructive and Aesthetic Surgery - February 24, 2014 Category: Cosmetic Surgery Authors: T. Tomouk, B. Mahler-Araujo, M.T.G. Gaskarth, C.M. Malata, P. Forouhi Tags: Correspondence and Communications - E-Only Publication Source Type: research
TTD consensus document on the diagnosis and management of exocrine pancreatic cancer
Abstract
Exocrine pancreatic cancer (PC) is a very aggressive and heterogeneous tumor with several cellular signaling pathways implicated in its pathogenesis and maintenance. Several risk factors increase the risk of developing PC. Therapeutic strategies used are dictated by the extent of disease. Supportive treatment is critical because of the high frequency of symptoms. For localized disease, surgery followed by adjuvant gemcitabine is the standard. Neoadjuvant and new adjuvant chemotherapy regimens are being evaluated. Locally advanced disease should respond best guided by a multidisciplinary team. Various tre...
Source: Clinical and Translational Oncology - September 25, 2014 Category: Cancer & Oncology Source Type: research
Predictive value of high‐density lipoprotein (HDL)‐cholesterol for cancer‐associated venous thromboembolism during chemotherapy
ConclusionsPatients with low HDL‐C have a 3‐fold higher risk of developing a first VTE episode during chemotherapy. Baseline analysis of HDL‐C levels might be of clinical value in predicting VTE in cancer out‐patients treated with anticancer drugs.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - September 1, 2014 Category: Hematology Authors: P. Ferroni, M. Roselli, S. Riondino, F. Guadagni Tags: Brief Report ‐ Clinical Haemostasis and Thrombosis Source Type: research
